Company Overview

Company Overview

Portola discovers and develops innovative therapeutics based on targets with established proof of concept that are designed to provide significant advances over current treatments for cardiovascular disease and autoimmune/inflammatory diseases.

Portola scientists have successfully collaborated for over 15 years on the discovery and development of novel small molecule agents targeting platelets, coagulation pathways and protein kinases. Our scientific team was the first to clone the platelet ADP receptor P2Y₁₂, the target of both Plavix® (clopidogrel) and our own ADP receptor antagonist, elinogrel. Our team was also instrumental in the discovery, development and commercialization of the leading GP IIb-IIIa inhibitor, INTEGRILIN® (eptifibatide).

Portola’s pipeline includes both proprietary and partnered products. In thrombosis, Portola is independently developing betrixaban, a Phase 3-ready, long-acting, oral, direct Factor Xa inhibitor, and its companion product, PRT064445, a recombinant Factor Xa inhibitor antidote. In inflammation, the company is collaborating with Biogen Idec to develop highly selective, novel oral Spleen Tyrosine Kinase (Syk)-specific kinase inhibitors, including the lead molecule, PRT062607, for the treatment of various autoimmune and inflammatory diseases. In addition to the Syk clinical programs, Portola’s broad chemistry capability has led to the discovery of potent, oral specific inhibitors of Janus Kinase (JAK), as well as dual inhibitors of Syk and JAK for chronic autoimmune indications and oncology. Portola is currently in a partnership with Novartis Pharma AG to develop elinogrel, an antiplatelet that is a direct-acting, competitive and reversible i.v. and oral P2Y₁₂ ADP receptor antagonist.